Key result
Edoxaban provides predictable pharmacokinetics without routine monitoring for AF stroke prevention and VTE treatment.
Edoxaban is a novel oral factor Xa inhibitor developed to provide predictable anticoagulation without the need for monitoring, overcoming the limitations of traditional therapies like warfarin.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Morishima et al. (2010) conducted a review in Thrombosis (Atrial Fibrillation, Venous Thromboembolism). Edoxaban vs. Warfarin, Enoxaparin was evaluated. Edoxaban is an oral, direct factor Xa inhibitor with predictable pharmacokinetics that does not require routine monitoring, developed for stroke prevention in atrial fibrillation and VTE treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: